Aclaris Therapeutics

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$1.34-$5.15
Market Cap
$645.2M
Shares Short
7M

Financials

See more
Revenue (12 Mos)
$8.3M
Revenue Growth (YoY)
37.2%
Gross Profit (12 Mos)
-$55.9M
Diluted EPS
-$0.56

News

See more

Yahoo Finance • 22 days ago

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Yahoo Finance • last month

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Yahoo Finance • 2 months ago

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Yahoo Finance • 3 months ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

About

CEO
Dr. Neal S. Walker D.O., M.D.
Address
701 Lee Road, Wayne, PA, United States, 19087
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
69